We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: Hội Chứng CKM
MedXY News
EnglishTag

Hội Chứng CKM

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Finerenone Shows Consistent Cardiovascular and Kidney Benefit Across CKM Syndrome Stages in Type 2 Diabetes and CKD
Cardiologychronic kidney diseasefinerenone

Finerenone Shows Consistent Cardiovascular and Kidney Benefit Across CKM Syndrome Stages in Type 2 Diabetes and CKD

By MedXY|Jun 7, 2026

A post hoc FIDELITY analysis suggests finerenone improves cardiovascular and kidney outcomes across CKM stages and may modestly shift patients toward CKM regression over time.

The Cardiovascular-Kidney-Metabolic (CKM) Syndrome Revolution: Mapping Medication Eligibility and Multi-Systemic Benefits
CardiologyGLP-1RAHội Chứng CKM

The Cardiovascular-Kidney-Metabolic (CKM) Syndrome Revolution: Mapping Medication Eligibility and Multi-Systemic Benefits

By MedXY|Mar 28, 2026

This review synthesizes recent evidence on the massive scale of CKM medication eligibility in the US, the synergistic effects of pharmacotherapy with lifestyle, and emerging neuropsychiatric benefits of GLP-1 receptor agonists.

The Rising Tide of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Synthesis of Medication Eligibility and Clinical Implementation
CardiologyGLP-1RAHội Chứng CKM

The Rising Tide of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Synthesis of Medication Eligibility and Clinical Implementation

By MedXY|Mar 18, 2026

This review synthesizes population-level data on the eligibility for GLP-1RAs, SGLT2is, and nsMRAs, highlighting that over 60% of US adults meet indications for these transformative therapies.

Intensive Blood Pressure Targets Below 130/80 mmHg Benefit Patients Across the Cardiovascular-Kidney-Metabolic Syndrome Spectrum
Cardiologycardiovascular riskHội Chứng CKM

Intensive Blood Pressure Targets Below 130/80 mmHg Benefit Patients Across the Cardiovascular-Kidney-Metabolic Syndrome Spectrum

By MedXY|Feb 24, 2026

A post hoc analysis of the CRHCP trial demonstrates that intensive blood pressure control (<130/80 mmHg) significantly reduces major adverse **Confirming JSON Structure** I’m now fully focused on creating the JSON object. I’v

Post-Heart Transplantation Survival Comes with a Heavy Cardiovascular-Kidney-Metabolic Burden: New Data on DM2 and CKD Risks
CardiologyHeart TransplantationHội Chứng CKM

Post-Heart Transplantation Survival Comes with a Heavy Cardiovascular-Kidney-Metabolic Burden: New Data on DM2 and CKD Risks

By MedXY|Dec 29, 2025

A longitudinal study of 944 heart transplant recipients reveals a staggering incidence of metabolic and renal dysfunction. While diabetes significantly increases mortality risk, the study highlights the potential of SGLT2 inhibitors and GLP

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities